LifeArc collaboration helps to advance a potential new cancer drug towards the clinic
Making our unique ULK inhibitors available as tools for the academic community has helped to reignite interest…
LifeArc works to bring new therapies and tests to patients. These case studies illustrate aspects of our work – to discuss how we can help please contact us.
Making our unique ULK inhibitors available as tools for the academic community has helped to reignite interest…
LifeArc’s scientists have been working on a fresh approach to drug discovery, using a parallel high-throughput application…
Technology transfer is a highly trained and multidisciplinary scientific endeavour, providing the crucial link between academic research…
While the development of COVID-19 vaccines has garnered much attention, scientists have also been looking at repurposed…
A team from LifeArc and Göttingen University has developed a new approach to intervene in early-stage treatment…
In 2020 the UK Government, supported by UK Research and Innovation and the National Institute for Health…
Our technology transfer team has helped the Medical Research Council (MRC), a founder in PepGen, to advance…
While much attention in the race for treatments for Covid-19 has been on the development of new…
A project by an industrial placement student led to Virtual Reality becoming a powerful tool for drug…
LifeArc is supporting MRC scientists who want to see their discoveries go from bench to bedside Age-related…
When MRC researchers achieved a new milestone in the emerging field of synthetic genomics, LifeArc set this…
Candidate drugs to treat the central nervous system could be screened with three-dimensional brain tissue grown in…
The World Health Organisation estimates around 10 million people across the world acquired tuberculosis (TB) in 2017.…
An experimental medicine to treat the rare inherited skin disorder epidermolysis bullosa (EB) is on track to…
In 2007, LifeArc entered a collaboration with Organon - ultimately acquired by Merck - to translate innovative…
The genetic abnormalities that lead to cancer can occur at any age. Cancer is the major cause…
LifeArc's joint venture with Pfizer, Bain Capital and OrbiMed With a purpose of working in partnership with…
A new approach to identifying antibacterial drug targets With the rapid increase in multi-drug-resistant (MDR) gram-negative bacteria,…
We have worked in partnership with Worldwide Cancer Research (WCR) since 2011 to ensure that intellectual property…
Through their shared dedication to patients, LifeArc and diagnostics company Biocartis are developing a ‘liquid biopsy’ test…
We collaborated with Renishaw Diagnostics Ltd. on a rapid diagnostic test for the detection of carbapenemase genes,…